Clinical Trial: Post Marketing Surveillance Study for MenQuadfi(R) [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07621653) titled 'Post Marketing Surveillance Study for MenQuadfi(R) [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea' on May 26.

Brief Summary: This surveillance is to investigate the safety profile of MenQuadfi(R), when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)*.

*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeli...